{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:39Z","timestamp":1793406459267,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002657","name":"Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Istanbul University Scientific Research Projects Unit","doi-asserted-by":"publisher","award":["39819"],"award-info":[{"award-number":["39819"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.micpath.2025.107560","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T17:57:38Z","timestamp":1744135058000},"page":"107560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["An assessment of cefiderocol's synergistic effects with eravacycline, colistin, meropenem, levofloxacin, ceftazidime\/avibactam, and tobramycin against carbapenem-resistant and -susceptible Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"204","author":[{"given":"Emel","family":"Matarac\u0131-Kara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-5081","authenticated-orcid":false,"given":"Bekir","family":"\u00d6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-7325","authenticated-orcid":false,"given":"Mesut","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"\u00d6zbek-\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.micpath.2025.107560_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx176","article-title":"Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"16","author":"Cai","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"6","key":"10.1016\/j.micpath.2025.107560_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3927","article-title":"Development and assessment of risk scores for carbapenem and extensive \u03b2-lactam resistance among adult hospitalized patients with Pseudomonas aeruginosa infection","volume":"5","author":"Tartof","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.micpath.2025.107560_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab554","article-title":"Early multicenter experience with Imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections","volume":"9","author":"Rebold","year":"2021","journal-title":"Open Forum Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2025.107560_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.05991-11","article-title":"Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections","volume":"56","author":"Pe\u00f1a","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.micpath.2025.107560_bib5","article-title":"Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies","volume":"5","author":"Elfadadny","year":"2024","journal-title":"Front. Microbiol."},{"issue":"11","key":"10.1016\/j.micpath.2025.107560_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3390\/pathogens13110975","article-title":"Multidrug resistant Pseudomonas aeruginosa in clinical settings: a review of resistance mechanisms and treatment strategies","volume":"13","author":"Schwartz","year":"2024","journal-title":"Pathogens"},{"issue":"2","key":"10.1016\/j.micpath.2025.107560_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations","volume":"15","author":"van Duin","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2025.107560_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107560_bib9","series-title":"Fetcroja (Cefiderocol). Prescribing Information","year":"2021"},{"issue":"5","key":"10.1016\/j.micpath.2025.107560_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/antibiotics11050579","article-title":"New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review","volume":"26","author":"Losito","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"9","key":"10.1016\/j.micpath.2025.107560_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia","volume":"20;64","author":"Biagi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.107560_bib12","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024-01-01 https:\/\/www.eucast.org\/clinical_breakpoints."},{"issue":"6","key":"10.1016\/j.micpath.2025.107560_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jacamr\/dlae183","article-title":"Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019\u201321","volume":"6","author":"Kocer","year":"2024","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"4","key":"10.1016\/j.micpath.2025.107560_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/1120009X.2020.1761172","article-title":"Evaluation of the synergy of ceftazidime\/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales","volume":"32","author":"Mataraci Kara","year":"2020","journal-title":"J. Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2025.107560_bib15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"1","author":"Hsueh","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.micpath.2025.107560_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.micpath.2025.107560_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.micpath.2025.107560_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-021-01063-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefiderocol","volume":"60","author":"Bilal","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"13","key":"10.1016\/j.micpath.2025.107560_bib19","article-title":"Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.micpath.2025.107560_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152132","article-title":"Evaluation of trimethoprim\/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXT-susceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.micpath.2025.107560_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0732-8893(02)00443-1","article-title":"Synergy of colistin with rifampin and trimethoprim\/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia","volume":"44","author":"Giamarellos-Bourboulis","year":"2002","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"1","key":"10.1016\/j.micpath.2025.107560_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.diagmicrobio.2004.09.002","article-title":"Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia","volume":"51","author":"Zelenitsky","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107560_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10096-022-04526-0","article-title":"Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa","volume":"42","author":"Sadek","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2025.107560_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107560_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101034","article-title":"Cefiderocol: clinical application and emergence of resistance","volume":"72","author":"Wang","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"6","key":"10.1016\/j.micpath.2025.107560_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics"},{"issue":"12","key":"10.1016\/j.micpath.2025.107560_bib27","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious diseases society of America guidance on the treatment of AmpC \u03b2-lactamase\u2013producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.107560_bib28","series-title":"35th Ed. CLSI Supplement M100 (ISBN 978-1-68440-262-5 [Print]; ISBN 978-1-68440-263-2 [Electronic])","article-title":"Performance standards for antimicrobial susceptibility testing","year":"2025"},{"issue":"12","key":"10.1016\/j.micpath.2025.107560_bib29","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025002852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025002852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:06:21Z","timestamp":1769202381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025002852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"alternative-id":["S0882401025002852"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107560","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An assessment of cefiderocol's synergistic effects with eravacycline, colistin, meropenem, levofloxacin, ceftazidime\/avibactam, and tobramycin against carbapenem-resistant and -susceptible Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.107560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107560"}}